Abstract: In some embodiments, the present invention provides tissue compositions including a first silk scaffold comprising a plurality of epithelial cells, a second silk scaffold comprising a plurality of stromal cells, and a plurality of neurons. In some embodiments, provided compositions can function as physiologically relevant corneal model systems for, inter alia, testing of therapeutics for corneal disease and/or injury and production of functional corneal tissue (e.g., for transplant, etc). The present invention also provides methods for making and using provided compositions.
Type:
Grant
Filed:
April 27, 2017
Date of Patent:
December 15, 2020
Assignee:
TRUSTEES OF TUFTS COLLEGE
Inventors:
David L. Kaplan, Siran Wang, Rachel Gomes, Chiara Ghezzi, Dana Cairns
Abstract: The present invention relates to an improved method for preservation of e.g. microorganisms, especially lactic acid bacteria, said method includes spray freezing.
Type:
Grant
Filed:
November 30, 2015
Date of Patent:
December 15, 2020
Assignee:
CHR. HANSEN A/S
Inventors:
Michelle Madsen, Allan Jensen, Hans Bisgaard-Frantzen
Abstract: Methods of using botulinum toxin based pharmaceuticals are disclosed. The methods cause vasodilatation and decreased flow resistance of certain vascular beds for the purpose of increasing blood flow to a region in order to positively impact deterioration from a number of diseases.
Abstract: Provided herein are methods of producing oils with reduced saturated fatty acids. The methods include culturing oil-producing microorganisms in a fermentation medium in the presence of one or more antifoaming agents under a controlled carbon consumption rate, wherein the culturing produces oils comprising fatty acids and wherein less than 35% of the fatty acids in the oil are saturated fatty acids.
Type:
Grant
Filed:
June 10, 2016
Date of Patent:
December 1, 2020
Assignee:
MARA Renewables Corporation
Inventors:
Zhiyong Sun, Alan Sothern, Kevin Berryman, Mercia Valentine, Michael Milway, Laura Purdue, Roberto E. Armenta
Abstract: A method for preventing the development of or treating GvHD complications in a mammalian patient which comprises administering to the mammal a population of cells enriched for STRO-1bright cells and/or progeny thereof and/or soluble factors derived therefrom.
Abstract: The invention provides a process of isolating or enriching a heavy metal present in a liquid medium. The process comprising the following steps: (a) incubating a suspension containing (i) particulate scrap metal, household waste and/or industrial waste containing a heavy metal in elemental form and (ii) biomass comprising a bacterium, or a combination of two or more bacteria, capable of binding the heavy metal; (b) separating the biomass having bound heavy metal from the suspension of step (a); and (c) isolating the heavy metal from the biomass separated in step (b).
Type:
Grant
Filed:
March 30, 2016
Date of Patent:
November 10, 2020
Assignee:
B.R.A.I.N. Biotechnology Research and Information Network AG
Inventors:
Stephen Gos, Andrea Christiansen, Xin Lu, Guido Meurer, Yvonne Tiffert, Esther Gabor, Benedikt Hoffmann, Martin Langer
Abstract: A method is disclosed for recovering living cells highly efficiently from cryopreserved cells by thawing and a system designed for such a method. The method for recovering living cells from cryopreserved cells includes thawing cryopreserved cells and diluting the thawed cell suspension with a diluent, wherein the dilution is performed in such a way that the maximum load of osmotic pressure at the time of dilution is equal to or less than 250 mOsm/second.
Abstract: The present invention provides a method of obtaining aggregates containing a rostral hypothalamus tissue and a rostral head ectodermal tissue, a hypophysis precursor tissue and a hypophysis hormone producing cell, by using a serum-free medium (preferably substantially free of growth factor and insulins), forming homogeneous aggregates of stem cells from pluripotent stem cells such as ES cell and the like, which are plated at a high cell concentration, and subjecting the formed aggregates to floating-culture.
Type:
Grant
Filed:
October 31, 2012
Date of Patent:
October 20, 2020
Assignees:
RIKEN, Sumitomo Chemical Company, Limited
Abstract: A photobioreactor system and a process for its use is illustrated, whereby water and nutrients from multiple sources are balanced (mixed using aeration) to the specific requirements of the particular photosynthetic organism strain used, sterilized, further mixed to balance the system and seeded with the photosynthetic microorganism, e.g. microalgae (dilution of a concentrated stock or added to an existing algal biomass). In accordance with such an embodiment, the algal biomass is then grown for a most efficient number of hours in a totally controlled environment where temperature (using aeration, an internal coil cooling system, or a combination thereof), pH (via CO2 delivery) and light delivery (using internal lighting directly inside the algal biomass) are optimized to the algal strain grown.
Type:
Grant
Filed:
February 20, 2019
Date of Patent:
October 20, 2020
Assignee:
Avespa Corporation
Inventors:
David Punchard, Philippe Bois, Angela Cortina Burgueno
Abstract: The present invention generally embraces the treatment of diseases by targeting cells expressing an antigen on the cell surface. In particular the invention relates to a method for stimulating, priming and/or expanding in vivo T cells genetically modified to express a chimeric antigen receptor (CAR) targeted to an antigen, comprising contacting the T cells with the antigen or a variant thereof in vivo. In one embodiment, the antigen or variant thereof is provided by administering a nucleic acid encoding the antigen or variant thereof.
Type:
Grant
Filed:
May 9, 2016
Date of Patent:
October 13, 2020
Assignees:
BIONTECH CELL & GENE THERAPIES GMBH, TRON—TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITÁTSMEDIZIN DER JOHANNES GUTENBERG—UNIVERSITÄT MAINZ GEMEINNÜTZIGE GMBH
Inventors:
Ugur Sahin, Katharina Reinhard, Petra Simon, Karolina Anna Mroz, Kathleen Hobohm
Abstract: Systems and methods are provided for deriving a platelet product from a plurality of buffy coats. A plurality of buffy coats are separately collected, for example, using a conventional floor centrifuge. Plasma and/or a platelet additive solution may be added to the buffy coats. The buffy coats are pooled into a container and conveyed into a centrifuge or are sequentially conveyed into the centrifuge without being pooled, where they are continuously processed to separate platelets from the other cellular blood components. The separated platelets are conveyed out of the centrifuge as a platelet product, which may be passed through a leukocyte removal filter to reduce the white blood cell content of the platelet product. By continuously separating the buffy coats, fewer buffy coats are required to produce a single-dose platelet product, while also allowing for the derivation and collection of a plurality of single-dose platelet products.
Type:
Grant
Filed:
September 15, 2017
Date of Patent:
September 15, 2020
Assignee:
Fenwal, Inc.
Inventors:
Kyungyoon Min, Benjamin E. Kusters, Richard I. Brown
Abstract: Disclosed herein are induced hepatocytes from a trophoblast stem cell, methods for inducing the cells, and compositions thereof. Also disclosed herein are methods of treating a disease or disorder (e.g., liver-associated) by utilizing an induced hepatocyte disclosed herein.
Type:
Grant
Filed:
September 15, 2017
Date of Patent:
September 8, 2020
Assignee:
ACCELERATED BIOSCIENCES CORP.
Inventors:
Jau-Nan Lee, Tony Tung-Yin Lee, Yuta Lee, Eing-Mei Tsai
Abstract: Provided is a method of inducing oligodendrocyte precursor cells (OPCs) through direct reprogramming from human somatic cells into which a nucleic acid molecule encoding an Oct4 protein or Oct4 protein-treated human somatic cells. The method of inducing OPCs by treating Oct4-overexpressing human somatic cells with a low molecular weight substance may establish OPCs with high efficiency in a short period of time through direct reprogramming without via neural stem cells, and thus the OPCs are useful as a cell therapeutic agent for an intractable demyelinating disease.
Type:
Grant
Filed:
June 3, 2019
Date of Patent:
September 8, 2020
Assignee:
Stemlab Inc.
Inventors:
Seung Kwon You, Won Jin Yun, Min Ji Park, Ji Yong Park
Abstract: Cells derived from postpartum tissue and products thereof having the potential to support cells of and/or differentiate to cells of a soft tissue lineage, and methods of preparation and use of those postpartum tissue-derived cells, are provided by the invention. The invention also provides methods for the use of such postpartum-derived cells and products related thereto in therapies for conditions of soft tissue.
Type:
Grant
Filed:
August 6, 2018
Date of Patent:
September 1, 2020
Assignee:
DePuy Synthes Products, Inc.
Inventors:
Laura J. Brown, Alexander M. Harmon, Anna Gosiewska
Abstract: The invention relates to a method for predicting the clinical response to a therapy based on the administration of mesenchymal stem cells (MSCs) in a patient suffering from an immune-mediated inflammatory disease. The invention also relates to methods of personalised medicine as well as to therapeutic uses of MSCs in a patient suffering from an immune-mediated inflammatory disease.
Abstract: A method for generating chondrocytes and/or cartilage, optionally articular like non-hypertrophic chondrocyte cells and/or cartilage like tissue and/or hypertrophic chondrocyte like cells and/or cartilage like tissue, the method comprising: a. culturing a primitive streak-like mesoderm population, optionally a CD56+, PDGFRalpha+ KDR? primitive streak-like mesoderm population, with a paraxial mesoderm specifying cocktail comprising: i. a FGF agonist; ii. a BMP inhibitor; optionally Noggin, LDN-193189, Dorsomorphin; and iii. optionally one or more of a TGFbeta inhibitor, optionally SB431524; and a Wnt inhibitor, optionally DKK1, IWP2, or XAV939; ?to specify a paraxial mesoderm population expressing cell surface CD73, CD105 and/or PDGFR-beta; b. generating a chondrocyte precursor population comprising: i. culturing the paraxial mesoderm population expressing CD73, CD105 and/or PDGFR-beta at a high cell density optionally in serum free or serum containing media; ii.
Abstract: The present invention relates to methods for removing antigens from tissues by sequentially destabilizing and/or depolymerizing cytoskeletal components and removing and/or reducing water-soluble antigens and lipid-soluble antigens. The invention further relates to tissue scaffolding and decellularized extracellular matrix produced by such methods.
Type:
Grant
Filed:
November 21, 2017
Date of Patent:
July 14, 2020
Assignee:
The Regents of the University of California
Inventors:
Leigh G. Griffiths, Angeliki Papalamprou, Maelene L. Wong
Abstract: The present invention relates to oligopeptide-free cell culture media comprising at least 0.5 mg/L of a polyamine and to methods for cultivating cells in said oligopeptide-free cell culture media comprising at least 0.5 mg/L of a polyamine. The invention also relates to methods for expressing at least one protein in a medium comprising at least 0.5 mg/L of a polyamine and to methods for producing at least one virus in a medium comprising at least 0.5 mg/L of a polyamine.
Type:
Grant
Filed:
August 7, 2017
Date of Patent:
June 30, 2020
Assignees:
Baxalta GmbH, Baxalta Incorporated
Inventors:
Leopold Grillberger, Manfred Reiter, Wolfgang Mundt, Artur Mitterer
Abstract: Means which enables preparation of a thick cell aggregate by a simple process without an operation of detaching and stacking of cells is disclosed. The method for preparing a three-dimensional cell aggregate by the present invention comprises: a cell encasing step of placing a cell suspension in a cell container; and a pressure application step of applying pressure to cells in the container. The cell encasing step and the pressure application step may be carried out a plurality of times. By the present invention, a thick, robust cell aggregate can be obtained by a simple operation of applying pressure to a cell suspension or a medium containing cells. Since the method does not require an operation of stacking a plurality of cell sheets, the cells are hardly damaged, and the conditions of the cells can be favorably maintained, so that the cells can be advantageously used as a tissue piece for transplantation.
Type:
Grant
Filed:
September 29, 2015
Date of Patent:
June 2, 2020
Assignees:
PUBLIC UNIVERSITY CORPORATION YOKOHAMA CITY UNIVERSITY, OSAKA UNIVERSITY, NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY